Lundbeck ‘Phases’ US Launch Of Long-Acting Vyepti In Migraine
Strategic Brands Drive Company’s Revenues In Q1
Lundbeck adapted its launch strategy for its quarterly injectable migraine therapy Vyepti because of the COVID-19 pandemic, becoming more virtual, and payer responses have been encouraging.
